A 2025 review in Endocrinology makes a provocative argument: researchers may learn more about PCOS by studying immune activity inside particular tissues than by treating one blood marker as evidence of whole-body chronic inflammation.
The review uses PCOS, so I use its term when describing the paper. Calling the condition PMOS does not change what this evidence can establish, and it does not create an inflammatory PMOS subtype.
The paper asks a better scientific question. That is not the same as giving patients a new diagnosis or protocol.
What did the review actually find?
The authors start with a problem in the existing literature. CRP is often higher on average in PCOS groups, but results for circulating cytokines such as IL-6 and TNF-alpha are inconsistent. A blood result also cannot show which tissue produced a signal or which tissue it affected.
The review therefore shifts the question from “Does PCOS cause chronic inflammation throughout the body?” to “How might immune and endocrine cells interact inside specific tissues?” It discusses work involving the hypothalamus, pituitary, ovaries, endometrium, adipose tissue, and other organs (De Robles et al. 2025).
That distinction matters. A single blood sample is a rough view of a complicated system. Tissue-level research may eventually explain why one immune signal has different effects in different organs or why apparently similar PCOS cases do not behave identically.
How early is the evidence?
The review combines human studies with animal and cell research. Human tissue is difficult to obtain, so much of the mechanistic work comes from rodent models. The authors themselves note that these models reproduce parts of the hormonal environment but cannot capture the full genetic and epigenetic complexity of human PCOS.
Some sections discuss possible immune-endocrine pathways in the ovary, endometrium, brain, and adipose tissue. “Possible” is doing real work there. Observing a difference, especially in an animal model, is not the same as showing that it caused PCOS in a woman or that changing it will improve a symptom.
The paper ends by calling for studies that establish causal relationships and discusses targeted immunotherapies as a future possibility (De Robles et al. 2025). If causality still needs to be established, a current consumer treatment cannot honestly be presented as the clinical consequence of the review.
What changes for someone with PCOS today?
I think the paper is worth reading precisely because it challenges a tidy story. It argues that “PCOS equals chronic systemic inflammation” may be too crude. Replacing that story with “PCOS equals hidden tissue inflammation” would make the same mistake one level deeper.
The review does not turn a normal CRP result into proof of hidden tissue inflammation, offer a clinical test for the proposed pathways, or validate an inflammatory PCOS subtype. Its discussion of targeted immunotherapies is a direction for future research, not support for an omega-3 product or treatment protocol now.
What changes is how researchers might investigate immune biology, not the standard diagnostic criteria or current patient tests. If you are trying to interpret a symptom, a “flare,” CRP, or ESR now, our inflammatory PCOS guide explains what that finding can and cannot show and how to frame the next step.
The honest takeaway is narrower and more useful than the sales version: immune-endocrine communication may matter in PCOS, tissue-specific research may reveal mechanisms that blood studies miss, and we do not yet know how to translate that into an individual diagnosis or treatment.